Under pharmacare, the 25 million Canadians who currently have private drug insurance plans will instantly have less coverage.
prescription drugs
Support among Canadians for national pharmacare drops from 79 per cent to 40 per cent when the plan is linked to tax hikes.
The Trump administration may not approve Florida’s drug import plan.
Review board’s new reference countries have more limited access to new and innovative drugs.
The original OHIP+ provided limited coverage to a population that largely didn’t need assistance.
U.S. pharmaceutical innovation has been disproportionately funded by U.S. consumers of patented drugs.
In most countries with universal health care, patients share the cost of treatment—surgical or pharmaceutical.
Under Medicare in the U.S., private insurers compete to offer coverage within regions.
Reform proposal misrepresents the nature of the global market and role of intellectual property.